These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37204419)

  • 41. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
    Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
    Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ; Tay SK; Teoh YL; Tok MY
    BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preference for Human Papillomavirus Self-Collection and Papanicolaou: Survey of Underscreened Women in North Carolina.
    Kilfoyle KA; Des Marais AC; Ngo MA; Romocki L; Richman AR; Barclay L; Brewer NT; Rahangdale L; Smith JS
    J Low Genit Tract Dis; 2018 Oct; 22(4):302-310. PubMed ID: 30179994
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L; Rémy V; Oyee J; Largeron N
    Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching clinic-based cervical cancer screening programs to human papillomavirus self-sampling: A cost-effectiveness analysis of vaccinated and unvaccinated Norwegian women.
    Pedersen K; Portnoy A; Sy S; Hansen BT; Tropé A; Kim JJ; Burger EA
    Int J Cancer; 2022 Feb; 150(3):491-501. PubMed ID: 34664271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccinating women previously treated for human papillomavirus-related cervical precancerous lesions is highly cost-effective in China.
    Zou M; Liu H; Liu H; Wang M; Zou Z; Zhang L
    Front Immunol; 2023; 14():1119566. PubMed ID: 37051255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
    Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
    Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mailing human papillomavirus self-sampling kits to women under-screened for cervical cancer improved detection in cervical cancer screening in a general population study in Japan.
    Nishimura Y; Matsuura M; Terada N; Nagao S; Shimada H; Isoyama K; Tamate M; Iwasaki M; Saito T
    BMC Public Health; 2023 Mar; 23(1):473. PubMed ID: 36906527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis.
    Smith MA; Hall MT; Saville M; Brotherton JML; Simms KT; Lew JB; Bateson D; Skinner SR; Kelaher M; Canfell K
    Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):268-277. PubMed ID: 33219163
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial.
    Winer RL; Lin J; Tiro JA; Miglioretti DL; Beatty T; Gao H; Kimbel K; Thayer C; Buist DSM
    JAMA Netw Open; 2022 Nov; 5(11):e2244343. PubMed ID: 36449291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
    Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
    J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of two invitation-based methods for human papillomavirus (HPV) self-sampling with usual care among un- and under-screened Māori, Pacific and Asian women: study protocol for a randomised controlled community trial to examine the effect of self-sampling on participation in cervical-cancer screening.
    Brewer N; Bartholomew K; Maxwell A; Grant J; McPherson G; Wihongi H; Bromhead C; Scott N; Crengle S; Cunningham C; Douwes J; Potter JD
    BMC Cancer; 2019 Dec; 19(1):1198. PubMed ID: 31815615
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits.
    Malone C; Tiro JA; Buist DS; Beatty T; Lin J; Kimbel K; Gao H; Thayer C; Miglioretti DL; Winer RL
    J Med Screen; 2020 Sep; 27(3):146-156. PubMed ID: 31744374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
    Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
    Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of strategies to increase cervical screening uptake at first invitation (STRATEGIC).
    Tsiachristas A; Gittins M; Kitchener H; Gray A
    J Med Screen; 2018 Jun; 25(2):99-109. PubMed ID: 28530515
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acceptability and Feasibility of Community-Based, Lay Navigator-Facilitated At-Home Self-Collection for Human Papillomavirus Testing in Underscreened Women.
    Mitchell EM; Lothamer H; Garcia C; Marais AD; Camacho F; Poulter M; Bullock L; Smith JS
    J Womens Health (Larchmt); 2020 Apr; 29(4):596-602. PubMed ID: 31532298
    [No Abstract]   [Full Text] [Related]  

  • 58. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
    Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
    Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
    Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
    Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.